相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability
Pierre Adumeau et al.
BIOCONJUGATE CHEMISTRY (2018)
Recent Advances in Zirconium-89 Chelator Development
Nikunj B. Bhatt et al.
MOLECULES (2018)
A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents
Nikunj B. Bhatt et al.
DALTON TRANSACTIONS (2018)
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET
Danielle J. Vugts et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection
Eric W. Price et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
A solid phase-assisted approach for the facile synthesis of a highly water-soluble zirconium-89 chelator for radiopharmaceutical development
Manon Briand et al.
DALTON TRANSACTIONS (2017)
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Gary A. Ulaner et al.
CLINICAL NUCLEAR MEDICINE (2017)
Scaling-down antibody radiolabeling reactions with zirconium-89
James C. Knight et al.
DALTON TRANSACTIONS (2016)
A comparative evaluation of the chelators H4octapa and CHX-A-DTPA with the therapeutic radiometal 90Y
Eric W. Price et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer
Jacob L. Houghton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
Brian M. Zeglis et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes
Malay Patra et al.
CHEMICAL COMMUNICATIONS (2014)
Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
Melissa A. Deri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy
Joseph R. Osborne et al.
JOURNAL OF UROLOGY (2014)
Enzyme-Mediated Methodology for the Site-Specific Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry
Brian M. Zeglis et al.
BIOCONJUGATE CHEMISTRY (2013)
The Growing Impact of Bioorthogonal Click Chemistry on the Development of Radiopharmaceuticals
Dexing Zeng et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry
Brian M. Zeglis et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
H4octapa-Trastuzumab: Versatile Acyclic Chelate System for 111In and 177Lu Imaging and Therapy
Eric W. Price et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
PET imaging with 89Zr: From radiochemistry to the clinic
Melissa A. Deri et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
Albert J. Chang et al.
PHARMACEUTICALS (2012)
Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry
Brian M. Zeglis et al.
BIOCONJUGATE CHEMISTRY (2011)
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography
Brian M. Zeglis et al.
DALTON TRANSACTIONS (2011)
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Devika Gajria et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86
Oluwatayo F. Ikotun et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load
Thijs H. Oude Munnink et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Jason P. Holland et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Targeting HER2 A report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials
Diane E. Milenic et al.
MABS (2010)
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
Maria J. W. D. Vosjan et al.
NATURE PROTOCOLS (2010)
Unconventional Nuclides for Radiopharmaceuticals
Jason P. Holland et al.
MOLECULAR IMAGING (2010)
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Eli C. F. Dijkers et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Standardized methods for the production of high specific-activity zirconium-89
Jason P. Holland et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
分享论文
